Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (421-430 of 636) with videos related to

Pageof 64
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2021
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH StudyMary J Thomson, Marina Serper, Vandana Khungar, et al.
Journal of Hepatology|May 18, 2024
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLDSamer Gawrieh, Eduardo Vilar-Gomez, Laura A Wilson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2023
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter StudyDaniel Q Huang, Noora Ahlholm, Panu K Luukkonen, et al.
Science Translational Medicine|June 8, 2022
Risk assessment with gut microbiome and metabolite markers in NAFLD developmentHowell Leung, Xiaoxue Long, Yueqiong Ni, et al.
Hepatology Communications|May 28, 2025
A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel frameworkAaron Hakim, Kung-Hung Lin, Tae-Hwi Schwantes-An, et al.
Cell Reports|December 16, 2016
Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating CellsXiaolin Luo, Rui Liao, Kaisa L Hanley, et al.
Hepatology (Baltimore, Md.)|May 19, 2023
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort studyBeom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, et al.
Hepatology Communications|May 16, 2025
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)Luis Antonio Díaz, Federica Tavaglione, Nikita Mittal, et al.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
The American Journal of Gastroenterology|September 14, 2019
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase LevelsSamer Gawrieh, Laura A Wilson, Oscar W Cummings, et al.
Pageof 64

Showing results (421-430 of 636) with videos related to

Sort By:
Pageof 64
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2021
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH StudyMary J Thomson, Marina Serper, Vandana Khungar, et al.
Journal of Hepatology|May 18, 2024
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLDSamer Gawrieh, Eduardo Vilar-Gomez, Laura A Wilson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2023
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter StudyDaniel Q Huang, Noora Ahlholm, Panu K Luukkonen, et al.
Science Translational Medicine|June 8, 2022
Risk assessment with gut microbiome and metabolite markers in NAFLD developmentHowell Leung, Xiaoxue Long, Yueqiong Ni, et al.
Hepatology Communications|May 28, 2025
A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel frameworkAaron Hakim, Kung-Hung Lin, Tae-Hwi Schwantes-An, et al.
Cell Reports|December 16, 2016
Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating CellsXiaolin Luo, Rui Liao, Kaisa L Hanley, et al.
Hepatology (Baltimore, Md.)|May 19, 2023
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort studyBeom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, et al.
Hepatology Communications|May 16, 2025
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)Luis Antonio Díaz, Federica Tavaglione, Nikita Mittal, et al.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
The American Journal of Gastroenterology|September 14, 2019
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase LevelsSamer Gawrieh, Laura A Wilson, Oscar W Cummings, et al.
Pageof 64